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by the health insurer. The IT systems of health insurers and hospitals need to 
be adapted. RecommendAtions: A working group led by the pharma industry 
association and major health insurers (including pharma companies, hospital 
administration and oncologists) will set up pilots with oncology clinics to test 
the feasibility of implementing an indication code and work on sustainable pric-
ing models for TCRs. conclusion: Goal would be a standardised processing of 
the remuneration for TCRs based on indication code and the underlying pricing 
model. For scale up the FOPH would have to mandate the adoption of the approach 
at national level.
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BAckgRound: The prospects of Brexit (UK exit from the EU) and Grexit (Greek exit 
from the Eurozone) have significant implications for the European pharmaceutical 
industry. In recent years, exiting the EU has been actively debated in the UK. While 
not a member of the Eurozone, the UK is a key member of the EU trade bloc. The 
UK government plans to hold a referendum by 2017; recent polls indicate 35-45% 
of Brits support withdrawal. In contrast, Greek withdrawal from the Eurozone may 
occur if the government is unable to reach an agreement with their creditors on 
the repayment of Greek sovereign debt. Failure to meet a € 1.6 billion payment to 
the IMF at the end of June 2015 may result in Eurozone withdrawal. impAct: As 
an EU member state, the UK forms a significant component of international refer-
ence pricing baskets for many other states; an arrangement which may or may not 
continue in the event of Brexit. Despite the independence of the British pound, 
Brexit may lead to further regional price disparity due to currency fluctuations. 
Both Brexit and Grexit are likely to have a significant impact on parallel trade 
amongst EU member states (parallel imports represent ~20% of UK drug sales, 
whereas exports for parallel trade account for ~12% of the Greek pharmaceutical 
market). Additionally, Grexit may impact the purchasing power of Greeks and their 
government’s ability to fund healthcare access to medicines. methodology: 
Navigant conducted qualitative interviews with payers and budget holders to 
understand expectations of the impact of Grexit and Brexit, anticipated strate-
gies in response to these withdrawals, the level of disruption to pharmaceutical 
supply and potential drug shortages. conclusions: Additional monitoring and 
appropriate planning is essential. The high level of uncertainty requires further 
consideration; Brexit and Grexit present significant implications to a broad array 
of stakeholders.
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BAckgRound: There are differences across the world in the definitions used to 
classify an orphan drug (OD), especially with respect to the prevalence of the dis-
ease justifying the orphan status and, the estimation of the population affected 
by the disease. oBjective: To identify the number of medicines which have been 
granted orphan designation in the United States (US) and European Union (EU), 
and analyse the approval trends over a ten-year time horizon. methods: All ODs 
authorised by the European Medicines Agency (EMA) and approved by the US Food 
and Drug Administration (FDA) were identified on the 1st May 2015 by downloading 
the databases available from their respective websites. Duplicates were removed 
in both cases using non-proprietary name and the lists were filtered to capture 
the period from 01/01/2005 to 31/12/2014. Results: The databases downloaded 
from the EMA and FDA had n= 93 and n= 237 results respectively. Removing the 
duplicates reduced these to n= 91 and n= 197 respectively. Filtering the list to select 
ODs authorised between the 01/01/2005 and 31/12/2014 gave final values of n= 74 and 
n= 189 respectively. ANALYSIS: The number of ODs approved significantly increased 
in numbers between the years 2005 and 2014 in the US and in the EU. In 2014 the 
EMA authorised 5 times as many ODs as they did in 2005 (15 vs 3 respectively) and 
a similar trend was observed in the US, where in 2014 the FDA authorised twice 
as many ODs as they did in 2005 (30 vs 14). conclusions: In 2005 the number of 
ODs authorised was significantly lower than that of 2014 and the designation of 
orphan diseases and approval of ODs was rare. 10 years on and gaining OD status 
for a sub population based rare disease appears from the outside to have become 
an objective for a number of pharmaceutical companies.
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oBjectives: To evaluate the potential for RSA implementation in Bulgaria and to 
outline the necessary legislative changes. methods: A literature review of the 
existing in EU RSA schemes and review of the local legislation were done to identify 
the laws and regulations intended for changes. Results: Bulgarian government has 
recently carried out major changes within the Health Insurance Act. The adopted 
texts introduced a “no discount - no reimbursement” rule, creation of HTA body 
and formal HTA assessment for all new and existing medicines with re-assessment 
every three years. The new HTA body is expected to adopt a threshold for cost-
effectiveness. Companies will be allowed to provide discounts for new medicines 
before reimbursement decision hence to influence the cost-effectiveness. The new 
measures are focusing mainly on the prices of the medicines, as were the old one 
(voluntary discounts to NHIF). The National Health Insurance Fund (NHIF) should 
consider other options which will give them opportunity for broader based negotia-
tions with the MAHs. As such option could be considered the implementation of RSA 
ance. conclusions: The following of protocols and guidelines for hernia repair 
has been shown to improve patient outcomes and reduce costs but the degree of 
uptake is variable. This suggests that there is scope for greater protocol/guideline 
adherence and resultant cost savings in hernia repair
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oBjective: France has large markets for pharmaceuticals in Algeria; moreover, 
Algerian authorities look to France for reference pricing. In recent times, the HAS 
is increasingly the influential health technology assessment (HTA) agency. French 
speaking countries are referencing and following the HAS decisions. The main objec-
tive of this study is to assess the HAS influence in North Africa region (Morocco, 
Algeria, Tunisia) in their reimbursement decisions. method: To have a comprehen-
sive study, a sample of medicines was determined, and these drugs had obtained 
positive recommendation by HAS during a period from January 2013 to December 
2013.Then, the recommendation from HAS were matched with the North African 
decision. Result: Total drugs approved for their first inscription were 258, where 
one drug obtained ASMR II, 12 obtained ASMR III, 13 noted ASMR IV and 232 ASMR 
V. When we have analyzed the common reimbursement decision taken according 
the level of ASMR We have observed that Morocco reimburse the drugs product with 
ASMR III and ASMR IV. However Algeria and Tunisia reimburse less the medicines 
with ASMR IV and V conclusion: This study demonstrates that the discordance 
between countries reimbursement decisions. In most cases it may reflect the dif-
ferences in the decision making process and in their constraint budget: Payers in 
Morocco are following HAS recommendation whereas Tunisia and Algeria there are 
following less HAS decisions.
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BAckgRound infoRmAtion: In 2014, Romania adopted a new legislation requiring 
Health_Technology_Assessment (HTA) as mandatory step in the drug reimbursement 
listing. The HTA System is a score-card, the drug/ a certain indication can be 
unconditional (80 – 145 points), or conditional approved (60-79 points). Conditional 
approved indications are reimbursed only if they are included in a cost-volume/cost-
volume-result contract (CV/CVR) with the National Payer,- requiring the tracking of 
drug utilisation data on indication. This could lead to differentiated pricing, depend-
ing on the benefit the product provides in different indications (Multiple Indication 
Pricing-MIP). One single unit price could be not relevant for all indications (e.g in 
oncology), especially when the same drug has both unconditional and conditional 
reimbursement. AppRoAch: Under MIP, drug utilisation would be tracked; the price 
of medicine per indication would be defined according to the benefit of the drug 
in that indication. Two approaches could be used: leverage existing national data 
collection by the National Payer, additionally collecting data like indication, treat-
ment status, result, etc. by a separate module in the Hospital Information System 
or use e-health/electronic patient records. Implications: Required minimum data 
fields, data format and attributes must be defined. Data must be complete, con-
sistent, available, allowing for validity checks. Marketing Authorization Holder 
(MAH) must receive reports containing information (anonymised and aggregated) 
on drug utilisation. To be defined: timing between data capturing and data avail-
ability, timing for paybacks, absorption of costs for data generation and capturing, 
error handling. RecommendAtions: Conduct pilot with a representative oncology 
clinic, set a methodology for collection, validation and use of data, generate reports, 
demonstrate the utility in managing CV/CVR. Scale up the project at national level 
through the National_Health_Insurance_House. conclusion: Developing a system 
to identify drug utilisation on indication, could support implementing conditional 
reimbursement schemes by the Payer and increase patient access to drugs.
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BAckgRound infoRmAtion: Targeted Combination Regimes (TCRs) could sig-
nificantly improve outcomes for cancer patients in future as drugs with different 
and complementary mechanisms of action often act synergistically to improve 
treatment results. Despite the potential benefits of TCRs there are also chal-
lenges associated with them. Several combination therapies involve more than 
one Marketing Authorization Holder, adding the cost of two medicines on top of 
each other combined with potentially longer therapy duration could make the 
funding of such TCRs unsustainable. The Federal_Office_of_Public_Health (FOPH) 
currently commands price negotiation at brand level, resulting in a single price per 
product, however in the future a more flexible pricing system might be required 
in order to enable fast patient access while making sure TCRs remain effective, 
expedient and economical. AppRoAch: One approach could be the introduction 
of an indication code on the billing process. The indication code could help health 
insurance companies to identify TCRs and allow a fast reimbursement through a 
simple and standardised process. Flexible pricing models would make sure that 
TCRs remain economical. implications: Patients would have to agree that infor-
mation on their condition (e.g. indication, molecular profile, therapy) would be 
captured on the billing process. The indication code would have to be encrypted 
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international agencies to mobilize resources to close the gap. The GFATM’s principal 
receptor identified a new international provider of ARVs, accounting for savings of 
USD 910 thousand. Finally, the MoH budgeted, for the first time, USD 1.9 million for 
the procurement of ARVs in 2013; turning the financial gap into a surplus USD 700 
thousand. For 2015 GFATM funding was 0%; however the DR Government covered 
a 100% of ARV needs and they have been executing USD 6.8 millions/per year. The 
decrease of the international financial assistance for ARV, particularly by the GFATM, 
can be covered by the commitment of national resources to bridge the financial gap 
and a more efficient use of the resources already available. The estimation of needs, 
consensus building methodologies, political incidence and advocacy strategies used 
in DR are guarantees of the financial sustainability for the following years.
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The number of newly developed and distributed health apps is legion and they are 
offered by healthcare providers, insurers and private companies alike. Although a 
sound business model is not always perceptible at first hand, it can be observed 
that in many cases payers and providers are either trying to bind patients with lock 
in effects and proprietary protocols or want to gather sensitive personal data for 
further use. New health care programs and solutions are rather made for market-
ing purposes than to serve the individual need of the customer (e.g. patient). Our 
project discusses the urgent need for regulatory rules ensuring that competition 
between providers of these health care apps serves the patients needs and leads 
to an improvement of patient relevant outcomes. In the course of the young lions 
“Health Parliament” the issue at hand was brought up by the authors in the board 
of competition at the example of the chronic disease of diabetes. To highlight the 
importance of continuous support in behavioral change we asked patients about 
their individual incentives and their expectations in a regulatory framework of 
health care competition to satisfy their needs. Following several discussions and a 
delphi-panel like process a regulatory framework was developed which could ensure 
that competitive forces act in a way that the patient’s needs are met for all kind of 
chronic diseases. To align the competitive forces onto patient centered outcomes 
the following aspects need to be addressed: 1) Market access; 2) Quality assurance; 
3) Protection of data privacy; 4) Open standards for interchangeability; 5) Pricing and 
reimbursement mechanisms. With our poster we would like to present our claims 
to an international audience to gain further insights on the topic and to foster the 
discussion into a more patient centered competition.
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BAckgRound: Maintaining chronic disease patients clinically stable after dis-
charge is an important imperative for avoiding costly hospital readmissions. 
A good understanding of the patient’s clinical risk profile is today considered 
the most important factor predictive of unfavorable patient outcomes. However, 
an often overlooked risk factor is patient behavior and patient decision drivers. 
Insights from the behavioral sciences can shed light on how individuals actu-
ally make decisions. Behavioral sciences have been used in marketing for years 
but are rarely used in the medical field. Recent studies from the UK have shown 
that up to 40% of the costs incurred for readmission/ emergency room visits are 
incurred by patients that should have been taken care of in the ambulatory care 
or at home. The behavioral drivers for these patients vary: not a good image of 
GPs, patients that are overly worried and anxious, an opportunity to get access to 
health care without an appointment. discussion: Not applying insights from the 
behavioral sciences to the medical field carries an important and avoidable cost 
for the health system caring for chronic disease patients. Healthcare should invest 
resources allowing to segment chronic disease patients at discharge, according 
to their behavioral profile, and provide support and education for those patients 
that are likely to burden the emergency rooms and hospitals for non-eligible 
reasons. conclusion: Profiling chronic disease patients at risk of costly hos-
pital readmissions based on insights from the behavioral sciences represents an 
opportunity to address an important cost driver that is currently overlooked in 
relation to the traditional clinical risk assessment.
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BAckgRound: Sofosbuvir, a breakthrough anti-HCV (hepatitis C virus) polymer-
ase inhibitor, was first approved for early entry in 2012 in France. The product was 
granted a marketing authorisation in the United-States (US) and in the European 
Union (EU), by the end of 2013 and beginning of 2014, respectively. Shortly after 
licensing, most HTA bodies assessed sofosbuvir; they acknowledged a major addi-
tional benefit and find it cost-effective for a price around USD 80,000 in US and 
USD 55,000 in EU for a 12-week course treatment. discussion: Sofosbuvir price 
may have led to health insurances (HI) bankruptcy in EU and to substantially 
increase HI premium in US. In EU, politicians reacted through an orchestrated 
media campaign; manufacturer was called to clarify the gap between production 
cost and price, as if price cost was the drug industry model, while value-based 
pricing was in force. The most active campaign happened in France where mem-
bers of parliament and Health Minister multiplied press releases and presence 
through legislative changes. Formal RSA should be mainly a non-outcome based as 
from health outcome based pay for performance looks the most feasible, consider-
ing the local NHIF capacity. Legislation changes should be made in chapter 12 of 
the Drug act, article 45 of the Insurance act and to be created new section within 
chapter 4 of Ordinance 10 of NHIF. RSA implementation will improve the access to 
lifesaving treatment options for the patients with unmet medical needs while the 
scarce NHIF budget will be preserved within endorsed limits. conclusions: RSA 
seems promising solution for balancing uncertainties for payers with market access 
for new and existing medicines, thus will allow NHIF efficiently to control and spend 
their limited budget while providing quality treatment to more patients in need.
PHP334
HealtH care coveraGe tHrouGH Private HealtH insurance
Kornfeld M1, Belgaied W2, Toumi M3
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, Tunis, Tunisia, 3Aix-Marseille University, 
Marseille, France
BAckgRound: Achieving universal health coverage (UHC) is a common goal world-
wide. As off today only some rich countries have succeeded to provide publically 
funded UHC to all their citizens. However, many low- and middle-income countries 
with a weak tax base are still far from achieving similar coverage despite a con-
tinuous increase in public and private healthcare expenditure. Patients in these 
countries have to rely on direct payments to finance their health care needs and in 
some regions these out-of-pocket (OOP) payments can account for up to 80 percent 
of total health expenditure. discussion: OOP represents a significant financial 
risk to households. Low-income families, in particular, are very vulnerable and run 
the risk of further impoverishment if they have to carry both health expenditures 
and indirect costs (loss of productivity) associated with their illness. Alongside 
public and out-of-pocket spending for covering patients private health insurance 
(PHI) represents an important third source of healthcare funding. PHI allows for 
risk-sharing and as such could play a critical role in securing low-income families 
access to treatment. So far, the contribution of PHI versus UHC remains limited but 
it is expected to grow significantly in the near future in emerging markets such 
as BRICS where it will be an important player for expanding the reach of novel 
treatments. The rapid economic growth, increased demand and gaps in healthcare 
coverage will pave the way for a greater uptake of PHI. In some African countries, 
despite PHI being urgently needed, extreme poverty may favor community based 
health insurance. conclusion: Due to the low tax base in developing countries 
UHC has problem to develop thus exposing the low/medium income households 
to high financial risk. Extending PHI in those countries allows for risk sharing and 
thus could have important equity implications.
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This study examines; along with current situation in Turkey, pharmaceutical pricing 
methods, reimbursement methods and basic health indicators, within the scope 
of changing pharmaceutical policies, in Turkey, reference countries and the United 
Kingdom, the implementations of which are of utmost importance for other coun-
tries. Upon the research conducted, it was detected that the pharmaceutical pricing 
in Turkey has been performed on the basis of reference pricing system that takes 
Italy, Portugal, Spain, Greece and France as reference. The regulations regarding the 
reimbursement process are determined by SSI. The reimbursement system has been 
changed numerous times and the discount rates has incrementally risen. In pricing, 
on the other hand, drug companies face difficulties in economic terms because of 
the fact that price discount of high rates are implemented over the reference price 
and that the European currency of Euro is fixed at 2. Moreover, it has also been 
recognized that certain drugs have been hard to find within the market and the 
patients’ access to medicines has become hindered. Although it is natural for Turkey 
to put restrictions on drugs budget to ensure sustainable drug financing, in order to 
maintain the existence of pharmaceutical industry and protect the patients’ access 
to medicines; it would be more favorable in the development of the industry that the 
expectations of the stakeholders in the industry are taken into account in the policy 
making process. This would also help the already supported R&D activities to be 
sustainable as well. The positive and negative aspects of Turkey’s offering the least 
expensive medicine should be examined. Whether being the country to supply the 
least expensive medicine is the correct objective or not in the international arena 
should seriously be discussed. It is recommended that how this situation affects 
Turkey’s image in the outer world should be scrutinized.
PHP336
closinG tHe financial GaP of antiretroviral and Hiv suPPlies for 
sustainaBility of Hiv national resPonse in tHe dominican rePuBlic
Valdez C1, Barillas E2, Diaz M3, Mesa A1
1Management Sciences for Health, Arlington, VA, Dominican Republic, 2Management Sciences for 
Health, Arlington, VA, WA, USA, 3Ministry of Health, santo domingo, Dominican Republic
Since 2004 public provision of ARV in Dominican Republic (DR) has been funded, 
by the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM). Until 2009 
there was a gross correspondence between the increase in the number of treated 
cases and the funding. From 2009 to 2012, however, the number of cases grew at 
an average rate of 33.4% (2,958 cases) per year, whereas funding experienced an 
average decrease of 21.7% (965,382 USD) per year. In 2012, the Ministry of Health 
(MoH) carried out the first national quantification exercise for the 2013 procure-
ment of medicines, under a standard forecasting methodology. The cost of ARV 
was estimated in USD 6.1 million; of which the GFATM would cover USD 3.6 million 
(59%). This was the first time that a financial gap of about USD 2.5 million (41%) was 
identified and recognized by all stakeholders. A political incidence and advocacy 
strategies based on evidence were established for national authorities, NGO’s and 
